Epigenetics Edge Position Epinoma as a specialized partner for blood test developers seeking faster, more accurate biomarker readouts via epigenetic signaling modulation, highlighting its first customer focus on the $50B blood test market and potential for recurring instrument and assay integration support.

Genomics SaaS Fit Leverage the company’s protein platform for reading and writing biological signals to offer collaboration opportunities with contract research organizations and diagnostic labs looking to enhance product performance, enabling joint go-to-market strategies and licensing deals.

Proof of Value Emphasize early-stage traction and revenue indicators to CDMO and lab customers, presenting case studies or pilot programs that demonstrate faster disease detection or improved test sensitivity, reducing development risk for potential buyers.

Strategic Partnerships Target mid-to-large cap diagnostics players with complementary portfolios (Invitae, NeoGenomics, Guardant Health, etc.) for co-development, data sharing, or platform integration opportunities to scale quickly as revenue grows.

Scalable Growth Highlight scalable tech stack and lean team as an advantage for rapid onboarding and cost-effective collaborations, offering flexible engagement models from joint research to commercial licensing to align with buyer budgets and timelines.